Health technologies have the potential to save millions of lives. New tools are needed to slow the global threat of diseases, including HIV/AIDS, malaria, tuberculosis, and neglected tropical diseases, and tackle many other pressing health needs. For diseases and conditions primarily affecting people in the world’s poorest places, there is little to no commercial market to spur R&D. Strong investment and innovative solutions are needed to catalyze the development of new technologies to bring health and opportunity in reach for all people.
The Hill featured an op-ed from GHTC Director Jamie Bay Nishi which highlights the historic decline in US government investment in neglected disease R&D and calls for the US to increase funding and reassert American leadership in global health innovation.
GHTC submitted a letter to the World Health Organization’s (WHO) Committee on the Selection and Use of Essential Medicines calling for it to approve the proposal to create an essential diagnostics list to complement the essential medicines list (EML). The letter, signed by 12 GHTC members, notes the impact that the EML has had on improving access to medicines and details the ways in which a diagnostics list would have similar impact.
Here at the GHTC, our team is dedicated to the idea that it’s possible to find new health solutions that will save countless lives around the world. From the first-ever vaccine to prevent malaria, to a ground-breaking gel that can prevent HIV infection, to new, simpler regimens to treat TB, we believe that science can and will deliver the tools we need to eliminate some of the world’s deadliest diseases.